Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease.

IF 4.5 2区医学 Q2 GERIATRICS & GERONTOLOGY Frontiers in Aging Neuroscience Pub Date : 2025-01-23 eCollection Date: 2025-01-01 DOI:10.3389/fnagi.2025.1501762

Yali Xu, Jie Zhang, Ying-Ying Shen, Wei-Wei Li, Bin Li, Hai-Ping Cheng, Gui-Hua Zeng

{"title":"Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease.","authors":"Yali Xu, Jie Zhang, Ying-Ying Shen, Wei-Wei Li, Bin Li, Hai-Ping Cheng, Gui-Hua Zeng","doi":"10.3389/fnagi.2025.1501762","DOIUrl":null,"url":null,"abstract":"Introduction: The role of the chemokine CX3CL1 in the processes of aging and Alzheimer's disease (AD) pathogenesis is well-established. This study aims to evaluate the diagnostic potential of urinary CX3CL1 levels in distinguishing between AD patients, those experiencing amnestic mild cognitive impairment (aMCI), and cognitively normal (CN) individuals.Methods: A cohort comprising 516 CN individuals across various age groups, 102 AD patients, and 65 subjects with aMCI was assembled, alongside 93 age- and sex-matched CN controls. Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify urinary CX3CL1 levels.Results: Urinary CX3CL1 concentrations exhibited an age-dependent increase and demonstrated a positive correlation with age. Comparatively, AD patients exhibited significantly elevated urinary CX3CL1 levels when contrasted with both the CN controls and the aMCI cohort. Conversely, aMCI patients displayed urinary CX3CL1 levels that were notably reduced in comparison to both the AD and CN groups.Conclusion: Urinary CX3CL1 levels correlate with the aging process and may serve as a potential diagnostic biomarker for both amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD).","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1501762"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798980/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Aging Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fnagi.2025.1501762","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The role of the chemokine CX3CL1 in the processes of aging and Alzheimer's disease (AD) pathogenesis is well-established. This study aims to evaluate the diagnostic potential of urinary CX3CL1 levels in distinguishing between AD patients, those experiencing amnestic mild cognitive impairment (aMCI), and cognitively normal (CN) individuals.

Methods: A cohort comprising 516 CN individuals across various age groups, 102 AD patients, and 65 subjects with aMCI was assembled, alongside 93 age- and sex-matched CN controls. Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify urinary CX3CL1 levels.

Results: Urinary CX3CL1 concentrations exhibited an age-dependent increase and demonstrated a positive correlation with age. Comparatively, AD patients exhibited significantly elevated urinary CX3CL1 levels when contrasted with both the CN controls and the aMCI cohort. Conversely, aMCI patients displayed urinary CX3CL1 levels that were notably reduced in comparison to both the AD and CN groups.

Conclusion: Urinary CX3CL1 levels correlate with the aging process and may serve as a potential diagnostic biomarker for both amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD).

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

尿CX3CL1对遗忘性轻度认知障碍和阿尔茨海默病的诊断潜力

趋化因子CX3CL1在衰老和阿尔茨海默病（AD）发病过程中的作用已得到证实。本研究旨在评估尿CX3CL1水平在区分AD患者、遗忘性轻度认知障碍（aMCI）患者和认知正常（CN）患者中的诊断潜力。方法：一个包括516名不同年龄组的CN个体、102名AD患者和65名aMCI患者的队列，以及93名年龄和性别匹配的CN对照组。采用酶联免疫吸附法（ELISA）定量尿CX3CL1水平。结果：尿CX3CL1浓度呈年龄依赖性升高，且与年龄呈正相关。相比之下，与CN对照组和aMCI队列相比，AD患者尿中CX3CL1水平明显升高。相反，与AD组和CN组相比，aMCI患者尿中CX3CL1水平明显降低。结论：尿CX3CL1水平与衰老过程相关，可能作为遗忘性轻度认知障碍（aMCI）和阿尔茨海默病（AD）的潜在诊断生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Aging Neuroscience GERIATRICS & GERONTOLOGY-NEUROSCIENCES

CiteScore

6.30

自引率

8.30%

发文量

1426

期刊介绍： Frontiers in Aging Neuroscience is a leading journal in its field, publishing rigorously peer-reviewed research that advances our understanding of the mechanisms of Central Nervous System aging and age-related neural diseases. Specialty Chief Editor Thomas Wisniewski at the New York University School of Medicine is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.